LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

Home・Aandelen Lijst・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Gesloten

4.94 5.11

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.7

Max

5.06

Belangrijke statistieken
By Trading Economics
Inkomsten	-10M -7.7M
Verkoop	-10M 529K
EPS	-0.056
Winstmarge	-1,463.516
Werknemers	44
EBITDA	-10M -7.7M

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-11M 869M
Vorige openingsprijs	-0.17
Vorige sluitingsprijs	4.94

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

3.255 / 3.365 Steun & Weerstand

Arbutus Biopharma Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 dec 2025, 17:39 UTC

Belangrijke Marktbewegers

Vanda Pharmaceuticals Rises on FDA Biologics License Application

15 dec 2025, 23:44 UTC

Marktinformatie

Gold Steady Ahead of U.S. Employment Report -- Market Talk

15 dec 2025, 23:38 UTC

Marktinformatie

Global Equities Roundup: Market Talk

15 dec 2025, 23:38 UTC

Marktinformatie

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

15 dec 2025, 22:19 UTC

Marktinformatie

Clean-Energy Project Developers Benefit From 'Deep Buyer Universe' -- Market Talk

15 dec 2025, 21:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

15 dec 2025, 21:42 UTC

Acquisities, Fusies, Overnames

Comcast Spinoff Versant Debuts at Modest Valuation, a Signal for a Warner Bros. Sale -- Barrons.com

15 dec 2025, 21:32 UTC

Acquisities, Fusies, Overnames

Comcast Spinoff Versant Debuts at Modest Valuation, Puts Warner Bros. Discovery in Focus -- Barrons.com

15 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

iRobot Files for Bankruptcy After Amazon Was Forced to Scrap Its Deal to Buy the Roomba Maker -- Barrons.com

15 dec 2025, 21:26 UTC

Acquisities, Fusies, Overnames

Commercial Metals Completes Acquisition of Foley Products for $1.84B >CMC

15 dec 2025, 21:23 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Reserves Right to Make Further Proposal If Circumstances Change

15 dec 2025, 21:23 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Does Not Intend to Submit Revised Takeover Proposal For Predictive

15 dec 2025, 21:23 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Notes Predictive Shares Trade at Discount to Value Implied By Perseus Proposal

15 dec 2025, 21:22 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Believes Revised Robex Merger Inferior to Its Own Takeover Proposal

15 dec 2025, 21:20 UTC

Acquisities, Fusies, Overnames

Commercial Metals Completes Acquisition Of Foley Products Company >CMC

15 dec 2025, 21:15 UTC

Acquisities, Fusies, Overnames

ServiceNow Completes Acquisition Of Moveworks >NOW

15 dec 2025, 21:00 UTC

Acquisities, Fusies, Overnames

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15 dec 2025, 20:57 UTC

Acquisities, Fusies, Overnames

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15 dec 2025, 20:36 UTC

Marktinformatie

Oil Futures Fall Further on Oversupply Concerns -- Market Talk

15 dec 2025, 20:31 UTC

Marktinformatie

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

15 dec 2025, 20:27 UTC

Marktinformatie

Acquisities, Fusies, Overnames

ServiceNow's Acquisition Streak Could Cause Investor Angst -- Market Talk

15 dec 2025, 20:15 UTC

Marktinformatie

El Buen Fin Helps Lift Mexican November Retail Sales -- Market Talk

15 dec 2025, 19:22 UTC

Marktinformatie

Gold and Silver Gain to Start Week -- Market Talk

15 dec 2025, 18:37 UTC

Marktinformatie

Oil Futures Extend Losses On Oversupply Worries -- Market Talk

15 dec 2025, 18:29 UTC

Marktinformatie

ServiceNow Seen Facing Pressure if Government Budgets Decline -- Market Talk

15 dec 2025, 17:58 UTC

Marktinformatie

Canada Housing Market In Search Of a Bottom -- Market Talk

15 dec 2025, 17:36 UTC

Marktinformatie

Canada Data Signal Underlying Price Pressures Persist -- Market Talk

15 dec 2025, 17:36 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

15 dec 2025, 17:36 UTC

Winsten

Texas Instruments Stock Slips. It Caught a Rare Downgrade From Goldman Sachs. -- Barrons.com

15 dec 2025, 17:30 UTC

Acquisities, Fusies, Overnames

Cinemark Stock Could Fall Even More If Netflix Buys Warner Bros., Analyst Says -- Barrons.com

Peer Vergelijking

Prijswijziging

Arbutus Biopharma Corp Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Arbutus Biopharma Corp - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.255 / 3.365Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.